# Nuclear substituted 2 hydroxymethane sulfamic acids and pharmaceutical compositions.

## Abstract
Nuclear substituted 2 hydroxyphenylmethane sulfamic acids and their pharmaceutically acceptable salts wherein the phenyl nucleus is substituted with 2 to 4 nuclear substituents and which are useful saluretic diuretics and anti inflammatories are disclosed. The products may be prepared by reacting nuclear substituted salicylaldehydes with ammonium sulfamate to generate intermediate imines which are reduced to afford the compounds of this invention.

## Claims
WHAT IS CLAIMED IS 1. A compound of the formula EMI22.1 wherein is is hydrogen lower alkyl lower alkoxy Xê is halogen or straight or branched chain lower alkyl X3 is hydrogen halogen lower alkyl or lower alkoxy X4 is halogen trifluoromethyl or lower alkyl thio and the non toxic pharmaceutically acceptable salts thereof. 2. A compound of the formula EMI22.2 whereinX1 is hydrogen alkoxy wherein the alkyl group has 1 3 carbon atoms X2 is halogen, branched chain alkyl wherein the alkyl group has 3 to 5 carbon atoms X is hydrogen, lower alkoxy having 1 to 3 carbon atoms X4 is halogen, trifluoromethyl, alkyl thio wherein the alkyl group has 1 to 3 carbon atoms and the non toxic pharmaceutically acceptable salts thereof. 3. A compound of the formula EMI23.1 whereinX1 is hydrogen or methoxy, x2 is chloro, iodo or branched chain lower alkyl wherein the alkyl group has 3 to 5 carbon atoms X3 is hydrogen or methoxy X4 is chloro, bromo, iodo, trifluoromethyl or methylthio and the non toxic pharmaceutically acceptable salts thereof. 4. A compound according to claim 3 which is 2 hydroxy 3 iodo 5 1,1 dimethylethyl phenylmethanesulf famic acid. 5. A compound according to claim 3 which is 2 hydroxy 3 , 5 diiodophenylmethanesulfamic acid. 6. A compound according to claim 3 which is 2 hydroxy 3 trifluoromethyl 5 1, 1 dimethylethyl phenyl methanesulfamic acid. 7. A compound according to claim 3 which is 2 hydroxy 3 methylthio 5 1, 1 dimethylethyl phenylmethane sulfamic acid. 8. A compound according to claim 3 which is 2 hydroxy 3,5 dichloro 4,6 dimethoxyphenylmethanesulfamic acid. 9. A pharmaceutical composition comprising a compound of the formulaEMI25.1 wherein xl is hydrogen lower alkyl lower alkox x2 is halogen or straight or branched chain lower alkyl is is hydrogen halogen lower alkyl or lower alkoxy X4 is halogen trifluoromethyl or lower alkyl thio and the non toxic pharmaceutically acceptable salts thereof along with a suitable pharmaceutical carrier.

## Description
TITLE OF THE INVENTION NUCLEAR S UB S TI TUTED 2 HYDROXYPHENYLMEThANE SULFAMIC ACIDS.ABSTRACT OF THE DISCLOSURE Nuclear substituted 2 hydroxyphenylmethanesulfamic acids and their pharmaceutically acceptable salts wherein the phenyl nucleus is substituted with 2 to 4 nuclear substituents and which are useful salureticdiuretics and anti inflammatories are disclosed. The products may be prepared by reacting nuclear substituted salicylaldehydes with ammonium sulfamate to generate intermediate imines which are reduced to afford the compounds of this invention.SUMMARY OF THE INVENTION This invention relates to a new class of chemical compounds which can be described generally as nuclear substituted 2 hydroxyphenylmethanesulfamic acids and to their nontoxic pharmaceutically acceptable salts. Pharmacological studies indicate that the instant products are effective diuretic and saluretic agents which can be used in the treatment of conditions associated with electrolyte and fluid retention and hypertension. When administered in a therapeutic dosage in conventional vehicles, the instant products effectively reduce the amount of sodium and chloride ions in the body, lower dangerous excesses of fluid to acceptable levels, and, in general, alleviate conditions usually associated with edema and hypertension. In addition, pharmacological studies indicate that the instant products of this invention are effective antiinflammatory agents which can be used in the treatment of inflammation when administered topically, orally, rectally or parenterally. When applied topically, the instant products are particularly effective in the treatment of dermatological disorders and like conditions, such as dermititis actimic, atopic, contact, eczematoid, seborrheic and stasis , herpetiformis, lichen planus, neurodermatitus, intitrigo, lichen simplex chronicus, and puritus, as well as for topical treatment of inflammation of the respiratory and intestinal mucosa, such as allergic rhinitus, bronchitis, bronchial asthma, bronchiectasis, colitis and the like. The nuclear substituted 2 hydroxyphenylmethanesulfamic acids of this invention are compounds having the following structural formula EMI2.1 I whereinX1 is hydrogen, lower alkyl of 1 to 3 carbon atoms, or lower alkoxy of 1 to 3 carbon atoms X2 is halogen or straight or branched chain lower alkyl wherein the alkyl group has up to 5 carbon atoms X3 is hydrogen, halogen, lower alkyl having up to 5 carbon atoms or lower alkoxy having up to 5 carbon atoms X4 is halogen, trifluoromethyl or loweralkylthio wherein the alkyl group has 1 to 3 carbon atoms and the non toxic pharmaceutically acceptable salts thereof. A more preferred aspect of this invention is constituted by those compounds of Formula I wherein x1 is hydrogen or lower alkoxy of 1 to 3 carbon atoms X is halogen or branched chain lower alkyl wherein the alkyl group has 3 to 5 carbon atoms X3 is hydrogen or lower alkoxy of 1 to 3 carbon atoms 4X is halogen, trifluoromethyl or alkylthio wherein the alkyl group has 1 to 3 carbon atoms and the non toxic pharmaceutically acceptable salts thereof. A most preferred embodiment of this invention consists of those compounds of Formula I wherein X1 and X3 are hydrogen or methoxy x2 is chloro, bromo, iodo or branched chain lower alkyl wherein the alkyl group has 3 to 5 carbon atoms X4 is chloro, bromo, iodo, trifluoromethyl or methylthio and the non toxic pharmaceutically acceptable salts thereof. The non toxic pharmaceutically acceptable salts mentioned above are those salts derived from the instant product sulfamic acids I and non toxic pharmaceutically acceptable bases such as the alkalai metal and alkaline earth metal hydroxides and amines. Especially preferred metal cations are those derived from alkalai metals, e.g., sodium, potassium, lithium and the like, and alkaline earth metals, e.g., calcium, magnesium and the like, and other metals, i.e., aluminum, iron and zinc.Pharmaceutically acceptable cations derived from primary, secondary or tertiary amines, or quaternary ammonium hydroxides are methylamine, dimethylamine, trimethylamine, ethylamine,N methylhexylamine, benzylamine, a phenethylamine, ethylene diamine, piperidene, morpholine, pyrrolidine, 1,4 dimethyl piperaz ine, ethanolamine, diethanolamine r triethanolamine, tris hydroxymethyl aminomethane, N methylglucamine,N methylglucosamine, ephedrine, procaine, tetramethylammonium hydroxide, tetraethylammonium hydroxide, benzyltrimethylammonium hydroxide and the like. Preferred specific compounds of this invention can be 2 hydroxy 3 iodo 5 1, 1 dimethylethyl phenyl methanesulfamic acid 2 hydroxy 3 , 5 diiodophenylmethanesulfamic acid 2 hydroxy 3 trifluoromethyl 5 1, 1 dimethylethyl phenylmethanesulfamic acid 2 hydroxy 3 methylthio 5 1,1 dimethylethyl phenylmethanesulfamic acid 2 hydroxy 3, 5 dichloro 4, 6 dimethoxyphenylmethane sulfamic acid. The nuclear substituted 2 hydroxyphenylmethanesulfamic acids of this invention of Formula IEMI4.1 wherein X11 X2, X3 and X4 are as previously defined can be prepared by the following major synthetic method, MethodA. A substituted salicylaldehyde of the formula EMI5.1 wherein X1, X2, X3 and X4 are as previously defined is made to react with ammonium sulfamate to give an intermediate imine of the formulaEMI5.2 wherein X11 X2 X3 and X4 are as previously defined which, in turn, is reduced with an alkalai metal borohydride reagent to afford, after acidification, the instant products of this invention of Formula I. A detailed description ofMethod A follows. 1 A substituted salicylaldehyde of Formula II wherein xl, X2, X3 and X are as previously defined is made to react with ammonium sulfamate in a suitable inert solvent, preferably methanol, ethanol and the like, at a temperature of 200C to the reflux temperature of the solvent, preferably 40 to 650C, for a period of 1 to 4 hours, preferably 1 1 2 to 2 hours, to generate in situ an intermediate imine ofFormula III.EMI5.3 2 An intermediate immine of Formula III wherein X1, X2, X3 and X are as previously defined is treated with a suitable alkalai metal borohydride reagent, preferably sodium or potassium borohydride, in a suitable solvent, preferably methanol, ethanol and the like, at a temperature of 0 to 400C, preferably 20 to 250C, for a period of 6 to 24 hours, preferably 12 to 20 hours, to afford, after acidification of the reaction mixture, the product 2 hydroxyphenylmethanesulfamic acid of Formula I.EMI6.1 A subgroup of compounds of this invention ofFormula IVEMI6.2 wherein X1, x2 and X3 are as previously defined and X4 is chloro, bromo or iodo can be synthesized by an alternate synthetic method, Method B, which is described below. A substituted salicylaldehyde of the formulaEMI7.1 wherein X1, X2 and X3 are as previously defined is made to react with ammonium sulfamate to give an intermediate imine of the formulaEMI7.2 wherein X1, X and X3 are as previously defined which, in turn, is reduced with a suitable alkalai metal borohydride reagent to provide, after acidification, a sulfamic acid of the formulaEMI7.3 wherein X1, X2 and X3 are as previously defined and which, upon halogenation, affords a product of Formula IV. A detailed description of method B follows. 1 A substituted salicylaldehyde of Formula V wherein X1, X2 and X3 are as previously defined is made to react with 2mumonium sulfamate in exactly the same manner as described in equation 1 of Method A to give an intermediate imine o EMI8.1 2 An intermediate imine of Formula VI wherein X1, X2 and X3 are as previously defined is treated with a suitable alkalai metal borohydride reagent exactly as described in equation 2 of Method A to afford a sulfamic acid ofFormula VII. EMI8.2 3 A sulfamic acid of Formula VII wherein X1, X2 and X3 are as previously defined is treated with a suitable halogenated reagent of the formula X4 Cl wherein X4 is as previously defined, preferably iodine monochloride, bromine monochloride or chlorine, in a suitable protic acidic medium such as aqueous acetic acid, aqueous tetrahydrofura and the like in the presence of an acid, preferably 3N hyd chloric acid, at a temperature of O to 80 C, preferably about 200 C, for a period of 1 to 10 hours, preferably 2 to 4 hours, to afford a compound of Formula IV. EMI9.1 Finally, those starting salicylaldehydes of the formulaEMI9.2 wherein X1, x2 and X3 are as previously defined and R is an alkyl group having 1 to 3 carbon atoms and which are not currently known in the art but are required for their ultimate conversion to the instant products of this invention by MethodA can be prepared by the following method.A phenol of the formulaEMI9.3 wherein X1, X2 and X3 are as previously defined is made to react with a dialkylsulfoxide of the formula RSOR wherein R is as previously defined in the presence of a strong acid to afford, after treatment with refluxing aqueous potassium chloride, a thioether of the formulaEMI10.1 wherein X1, X2 and X3 are as previously defined which is then amidomethylated and the resulting amide subsequently hydrolyzed to give a benzylamine hydrochloride of the formulaEMI10.2 which is treated with hexamethylenetetramine followed by acid hydrolysis to afford the desired salicylaldçhyde ofFormula VIII. Details of this method follow. 1 A phenol of Formula IX wherein X1, X2 and X3 are as previously defined is reacted with a dialkylsulfoxide of the formula RSOR such as dimethylsulfoxide and the like in the presence of a suitable dehydrating agent, preferably phosphorous oxychloride, in a suitable acidic medium, preferably 70 perchloric acid, at a temperature of 0 to 400C, preferably about 200C, for a period of 12 to 24 hours1 preferably 15 to 18 hours, to give an intermediate adduct which upon treatment with a saturated aqueous solution of an alkalai metal halide, preferably sodium or potassium chloride, at the reflux temperature of the solution for a period of 2 to 6 hours, preferably about 4 hours, provides a thioether ofEMI11.1 2 A thioether of Formula X wherein X1, Xê, X and R are as previously defined is amidomethylated using suitable N hydroxymethylamide of the formula wherein R1 is an acyl moiety, HOCH2NHR moietyl RÚ is an acyl moiety, preferably 2,2,2 trifluoro acetyl, 2,2,2 trichloroacetyl or 2 chloroacetyl, in the presence of a mineral acid to. give an intermediate amide which upon hydrolysis in an acidic medium, preferably ethanol 12N hydrochloric acid, affords a benzylamine hydrochloride of Formula XI. The details of this amidomethylation hydrolysis step are described in U.S. Patent 4,029,816 which issued June 14, 1977.EMI11.2 3 A benzylamine hydrochloride of Formula XI wherein xl, X2, X3 and R are as previously described is treated with hexamethylenetetramine in a suitable acidic medium, preferably aqueous acetic acid, at the reflux temperature of the medium for a period of 2 to 12 hours, preferably about 4 hours, followed by treatment with a strong mineral acid, preferably hydrochloric acid, at the reflux temperature of the reaction mixture for a brief period, preferably 10 to 30 minutes, to afford a salicylaldehyde of Formula VIII.EMI12.1 The examples which follow illustrate the nuclear substituted 2 hydroxyphenylmethanesulfamic acids of this invention and the methods by which they are prepared. EXAMPLE 1Preparation of 2 Hydroxy 3 iodo 5 1, 1 dimethylethyl phenyl methanesulfamic acidStep A. Preparation of 2 Hydroxy 5 1, 1 dimethylethyl phenylmethanesulfamic acid A solution of 5 l,1 dimethylethyl salicylaldehyde 3.56 g., 0.02 mole and ammonium sulfamate 2.28 g., 0.02 mole in anhydrous methanol 100 ml. is stirred and heated at reflux for 1 1 2 hours. The resulting clear, yellow solution is cooled to 5 100C, treated with sodium borohydride 0.76 g., C.02 mole added portionwise over 5 minutes and stirred at 200C for 20 hours.Evaporation of the solvent in vacua leaves a residue which is treated with water 150 ml. the resulting heterogeneous mixture is cooled to 0 50C, cautiously acidified with 12N hydrochloric acid and filtered to give 2.3 g. 44.3 of 2 hydroxy 5 1 r l dimethylethyl phenylmethanesulfamic acid.m.p. 260 262 C with dec. Recrystallization from ether tetrahydrofuran 5 1 v v affords an analytical sample of 2 hydroxy 5 1,1 dim thylethyl phenylmethanesulfamic acid as colorless crystals, m.p. 264 2650C with dec.Step B. Preparation of 2 Hydroxy 3 iodo 5 l,l dimethyl ethyl henylmethanesulfamic acid To a solution of 2 hydroxy 5 l,l dimethylethyl phenylmethanesulfamic acid 2.6 g., 0.01 mole in watertetrahydrofuran 5 1 v v 90 ml. is added a freshly prepared solution of iodine monochloride 1.64 g., 0.01 mole in 3N hydrochloric acid 12 ml. portionwise over 5 minutes providing a dark reaction solution which is stirred at 200C for 2 hours and then cooled to 0 50C. The resulting insoluble solid is collected, washed with 12N hydrochloric acid, dried with aspiration at 200C and washed with water to give crude 2 hydroxy 3 iodo 5 l,ldimethylethyl phenylmethanesulfamic acid 3.3 g., 85.9 , m.p. 172 1800C with dec. Recrystallization from waterethanol 10 1 v v provides pure 2 hydroxy 3 iodo 5 1,1 dimethylethyl phenylmethanesulfamic acid as colorless crystals, m.p. 180 1820C with dec. EXAMPLE 2Preparation of 2 Hydroxy 3,5 diiodophenylmethanesulfamic acid Ethanol Solvate tep A Preparation of 2 Hydroxyphenylmethanesulfamic acid This compound is prepared essentially by the same method as described in Example 1, Step A, except that the 5 1,1 dimethylethyl salicylaldehyde is replaced by salicyl aldehyde. The following reagents are employed salicylaldehyde . . . ç . e ç .... gs t . 4.6 g., 038 mole ammonium sulfamate . . , . . . . , . 4.0 g., 0.035 mole methanol . . . . . . . . . . . . . . . . 100 ml.sodium borohydride . . . 4 . . . . . 1.44 g., 0.038 mole Concentration of the reduction mixture leaves a residual solid which is dissolved in water 400 ml. . The resulting solution is treated with 12N hydrochloric acid 5 ml. and filtered to provide an aqueous solution of 2 hydroxyphenylmethanesulfamic acid which is used directly in Step B described below without further purification.Step B. Preparation of 2 ydroxy 3,5 diiodophenylmethane sulfamic acid Ethanol Solvate To the aqueous solution of 2 hydroxyphenylmethanesulfamic acid ca. 0.035 mole described in Step A above is added a freshly prepared solution of iodine monochloride 11.37 g., 0.070 mole in 3N hydrochloric acid 60 ml. ortionwise over 5 minutes. The resulting reaction mixture is stirred at 200C for 16 hours and filtered.The collected ale yellow solid is washed with 12N hydrochloric acid, airtried with aspiration, washed with ether and crystallized trom ether ethanol 14 1 v v 300 ml. to afford 2 hydroxy 3,5 diiodophenylmethanesulfamic acid ethanol olvate as pale yellow crystals 10.5 g., 60 , m.p. 168 170 C with dec. Recrystallization from ether ethanol 8 1 v v gives analytically pure 2 hydroxy 3,5 diiodophenylmethanesulfamic acid ethanol solvate, m.p. 172 1730C. with dec. EXAMPLE 3Alternate Preparation of 2 Hydroxy 3 iodo 5 1,1 dimethyl ethyl phenylmethanesulfamic AcidStep A Preparation of 3 Iodo 5 1,1 dimethylethyl sali cylaldehyde To a solution of 2 aminomethyl 4 l,l dimethylethyl 6 iodophenol hydrochloride 51.3 g., 0.15 mole in acetic acid water 11 3 v v 1.4 1. is added a solution of hexamethylenetetramine 22.05 g., 0.158 mole in water 75 ml. providing a clear solution which is stirred and heated at reflux for 4 hours. The reaction mixture is treated with 4.5N hydrochloric acid 225 ml. and heated at reflux for 15 minutes. Upon slowly cooling to 100C, the 3 iodo 5 1,1 dimethylethyl salicylaldehyde is deposited as pale yellow crystals 20.4 g., 44.7 , m.p. 76 780C.Sublimation gives analytically pure 3 iodo 5 l,l dimethyl ethyl salicylaldehyde, m.p. 770C.Step B Preparation of 2 Hydroxy 3 iodo 5 1,1 dImethyl ethyl phenylmethanesulfamic acid This compound is prepared essentially by the same method as described in Example 1, Step A, except that the 5 1,1 dimethylethyl salicylaldehyde is replaced by 3 iodo5 1,1 dimethylethyl salicylaldehyde. The following reagents are employed 3 iodo 5 1 ,l dimethylethyl salicylaldehyde ............... 6.08 g., 0.02 mole ammonium sulfamate .................... 2.28 g., 0.02 mole methanol ..................... 100 ml.sodium borohydride .................. 0.76 g., 0.02 mole water .............................. 150 ml.12N hydrochloric acid ether tetrahydrofuran 5 1 v v This procedure affords analytically pure 2 hydroxy3 iodo 5 1,1 dimethylethyl phenylmethanesulfamic acid, m.p.180 1820C with dec., which is identical with the authentic 2 hydroxy 3 iodo 5 1,1 dimethylethyl phenylmethanesulfamic acid described in Example 1, Step B. EXAMPLE 4Preparation of 2 hydroxy 3 bromo 5 1, 1 dimethylethyl phenylmethanesulfamic acid By following essentially the same procedures described in Example 3 but beginning with 2 aminomethyl 4 1,1 dimethylethyl 6 bromophenol hydrochloride instead of 2aminomethyl 4 1,1 dimethylethyl 6 iodophenol hydrochloride, there are obtained successively,Step A, 3 bromo 5 1, 1 dimethylethyl salicylaldehyde Step B, 2 hydroxy 3 bromo 5 1, 1 dimethylethyl phenyl methanesulfamic acid. EXAMPLE 5Preparation of 2 Hydroxy 3 chloro 5 1,1 dimethylethyl phenyl methanesulfamic acid By following essentially the same procedures described in Example 3 but beginning with 2 aminomethyl 4 1,1 dimethylethyl 6 chlorophenol hydrochloride instead of 2 aminomethyl 4 1,1 dimethylethyl 6 iodophenol hydrochloride, there are obtained successively Step A, 3 chloro 5 1,1 dimethylethyl salicylaldehyde Step B, 2 hydroxy 3 chloro 5 1, 1 dimethylethyl phenyl methanesulfamic acid. EXAMPLE 6Preparation of 2 Hydroxy 3 trifluoromethyl 5 1, l dimethyl ethyl phenylmethanesulfamic acid This compound is prepared essentially by the same method described in Example 1, Step A, except that the 5 1,1 dimethylethyl salicylaldehyde is replaced by 3 trifluoromethyl 5 1,1 dimethylethyl salicylaldehyde. Thereby is obtained 2 hydroxy 3 trifluoromethyl 5 1, 1 di methylethyl phenylmethanesulfamic acid. EXAMPLE 7Preparation of 2 Hydroxy 3 , 5 dichloro 4, 6 dimethoxyphenyl methanesulfamic acid This compound is prepared essentially by the same procedure as described in Example 1, Step A, except that the 5 l,l dimethylethyl salicylaldehyde is replaced by 3,5 dichloro 4,6 dimethoxysalicylaldehyde. Thereby is obtained 2 hydroxy 3, 5 dichloro 4, 6 dimethoxyphenylmethanesulfamic acid. EXAMPLE 8Preparation of 2 Hydroxy 3 methylthio 5 1 ,l dimethylethyl phenylmethanesul famic acidStep A Preparation of 2 Methylthio A l,l dimethylethyl phenol To a cold 0 50C suspension of 4 l,l dimethylethyl phenol 7.5 g., 0.05 mole and phosphorous oxychloride 8 ml. in 70 perchloric acid 10 ml. is added dimethylsulfoxide 3.9 g., 0.05 mole dropwise with vigorous stirring.The resulting reaction mixture is stirred at 0 50C for 1 hour and at 200C for 16 hours and then poured onto crushed ice whereupon a gum separates. Upon warming to 20eC with vigorous stirring there is obtained a white solid which is collected, washed with cold water, air dried at 200C with aspiration and washed with ether. The white solid 10 g., m.p. 1600C is added to saturated aqueous potassium chloride 100 ml. and the resulting mixture, heated at reflux for 4 hours. After standing at 20 C for 12 hours, the reaction mixture is extracted with ether. The ethereal extract is washed with water and saturated brine, dried over sodium sulfate and filtered.Evaporation of the filtrate in vacuo leaves 2 methylthio 4 1 ,l dimethylethyl phenol as an analytically pure, colorless oil 5.7 g., 58 . Elemental analysis for C11H16OS Calc. C, 67.30 H, 8.22. Found C, 66.91, H, 8.22.Step B. Preparation of 2 Aminomethyl 4 1 ,l dirrethy1ethy1 6 methylthio phenol . hydrochloride Pulverized N hydroxymethyl 2 chloroacetamide 3.32 g., 0.027 mole is added portionwise over 15 minutes to a solution of 2 methylthio 4 l,l dimethylethyl phenol 5.3 g., 0.027 mole and conc. sulfuric acid 10 ml. in acetic acid 150 ml. cooled in an ice bath. The resulting reaction mixture is stirred at 200C for 16 hours and then poured into ice water 1 1. whereupon a white gum is deposited. The gum is extracted with ether and the etheral extract, washed well with water and saturated brine. Removal of the solvent under reduced pressure leaves a residual solid which is dissolved in ethanol 30 ml. . The resulting solution is treated with 12N hydrochloric acid 15 ml. and heated at reflux for 4 hours.Evaporation in vacuo affords a residual solid which is triturated with ether and collected by filtration to give crude 2 aminomethyl 4 l,l dimethylethyl 6 methylthio phenol hydrochloride 5.4 g., 76.4 , m.p. 150 1770C. Two recrystallizations from ether ethanol 10 1 v v followed by recrystallization from 12N hydrochloric acid provides analytically pure 2 aminomethyl 4 l,l dimethylethyl 6 methylthio phenol hydrochloride as colorless crystals, m.p. 180 181.50C.Step C Preparation of 3 Methylthio 5 l,l dimethylethyl salicylaldehyde This compound is prepared essentially by the same procedure as described in Example 3, Step A, except that the 2 aminomethyl 4 1 ,1 dimethylethyl 6 iodophenol hydrochloride is replaced by 2 aminomethyl 4 1,1 dimethylethyl 6 methylw thio phenol hydrochloride. Thereby is obtained 3 methylthio 5 1, 1 dimethylethyl salicylaldehyde. Step D Preparation of 2 Hydroxy 3 methylthio 5 l,l di methylethyl phenylmethanesulfamic acid This compound is prepared essentially by the same procedure as described in Example 1, Step A, except that the 5 1,1 dimethylethyl salicylaldehyde is replaced by 3 methylthio 5 1, 1 dimethylethyl salicylaldehyde. Thereby is obtained 2 hydroxy 3 methylthio 5 1, 1 dimethylethyl phenylmethanesul famic acid. The novel compounds of this invention are diuretic and saluretic agents which can be administered in a wide variety of therapeutic dosages in conventional vehicles as, for example, by oral administration in the form of a tablet or by intravenous injection. Also, the daily dosage of the products may be varied over a wide range varying from 5 to 2,000 mg. The product is preferably administered in subdivided doses in the form of scored tablets containing 5, 10, 25, 50, 100, 150, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. These dosages are well below the toxic or lethal dose of the products which may be administered in a total daily dosage of from 100 mg. to 2,000 m. in a pharmaceutically acceptable carrier. A suitable unit dosage form of the products of this invention can be administered by mixing 50 milligrams of a nuclear substituted 2 hydroxyphenylmethanesulfamic acid I or a suitable salt thereof, with 149 mg. of lactose and 1 mg. of magnesium stearate and placing the 200 mg. mixture into a No. 1 gelatin capsule. Similarly, by employing more of the active ingredient and less lactose, other dosage forms can be put up in No. 1 gelatin capsules and, should it be necessary to mix more than 200 mg. of ingredients together, larger capsules may be employed. Compressed tablets, pills, or other desired unit dosages can be prepared to incorporate the compounds of this invention by conventional methods and, if desired, can be made up as elixirs or as injectable solutions by methods well known to pharmacists. The following example is included to illustrate the preparation of a representative dosage form EXAMPLE 9Dry filled capsules containing 50 mg. of active ingredient per capsule Per Capsule 2 hydroxy 3 iodo 5 1, 1 dimethyl ethyl phenylmethanesulfamic acid 50 mg. lactose 149 mg.magnesium stearate 1 mg.Capsule Size No. 1 200 mg. The 2 hydroxy 3 iodo 5 1,1 dimethylethyl phenyl methanesulfamic acid is reduced to a No. 60 powder and ther lactose and magnesium stearate are passed through a No. 6C bolting cloth onto the powder and the combined ingredients admixed for 10 minutes and then filled into a No. 1 dry gelatin capsule. Similar dry filled capsules can be prepared by replacing the active ingredient of the above example by any of the other novel compounds of this invention.